Unternehmens-Profil
Gilead Sciences Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines addressing unmet medical needs in infectious diseases, oncology, and other therapeutic areas across the United States, Europe, and international markets. Its portfolio centers on HIV treatments, including leading products like Biktarvy, Genvoya, Descovy, Odefsey, Sunlenca, and Yeztugo, the world's first twice-yearly HIV prevention therapy. The company also offers therapies for viral hepatitis such as Epclusa, Harvoni, Vemlidy, and Viread, alongside Veklury for COVID-19. In oncology and cell therapy, Gilead provides Yescarta, Tecartus, and Trodelvy for various cancers, as well as Livdelzi for primary biliary cholangitis. These products target life-threatening conditions in virology, liver diseases, hematology, inflammation, and respiratory areas, serving patients through innovative antiviral regimens, CAR-T cell therapies, and antibody-drug conjugates. Founded in 1987 and headquartered in Foster City, California, Gilead Sciences Inc. plays a pivotal role in advancing treatments for chronic and infectious diseases globally.
Bewertungs-Kennzahlen
Allgemeine Finanzkennzahlen
Chart · 90 Tage
Letzter Kurs: 134,24 USD· Stand 07.05.2026
News · Gilead Sciences, Inc.
- GILD Beats Q1 Earnings and Sales Estimates, Lowers '26 EPS View
- Gilead Sciences, Inc. (GILD) Q1 2026 Earnings Call Transcript
- Gilead (GILD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
- Gilead Sciences (GILD) Tops Q1 Earnings and Revenue Estimates
- Gilead Sciences Expects Loss This Year on Acquired R&D Expenses